Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | INMUNOSUN-SOGUG trial: sunitinib second line metastatic RCC

Enrique Grande • 29 May 2020
ASCO 2020
Kidney Cancer Sunitinib
INMUNOSUN-SOGUG

Enrique Grande, MD, of the MD Anderson Cancer Center Madrid, Madrid, Spain, highlights data coming from the INMUNOSUN-SOGUG trial (NCT03066427), a prospective phase II study investigating the efficacy of second line sunitinib, a tyrosine kinase inhibitor, in patients who have failed first line, immunotherapy treatment. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Enrique Grande

1:39
Emerging biomarkers of ADC response and toxicity in urothelial carcinoma
Enrique Grande • 25 Jan 2024
2:30
The future of antibody-drug conjugates in urothelial cancer
Enrique Grande • 25 Jan 2024
1:58
What’s next for antibody drug conjugates in urothelial carcinoma?
Enrique Grande • 25 Jan 2024
1:23
CABATEN/GETNE-T1914: cabozantinib plus atezolizumab in adrenocortical carcinoma
Enrique Grande • 25 Jan 2024

Related Videos

2:52
LITESPARK-004: ESA use in VHL disease-associated RCC
Benjamin Maughan • 26 Jan 2024
3:04
Evaluating the role of radiotherapy in primary and metastatic RCC
Sophia Kamran • 26 Jan 2024
2:14
Managing renal cell carcinoma after progressing on checkpoint inhibitors
David Braun • 14 Feb 2024
1:24
The emerging benefits of adjuvant checkpoint inhibition in RCC
David Braun • 26 Jan 2024
The content of VJOncology is intended for healthcare professionals